United States: Strong Support For Sequenom's Petition For Rehearing En Banc

Last Updated: September 15 2015
Article by Andrew D. Cohen and Irena Royzman

In Ariosa Diagnostics Inc. v. Sequenom Inc., 788 F.3d 1371 (Fed. Cir. 2015), a Federal Circuit panel held that Sequenom Inc.'s prenatal diagnosis patent claims patent ineligible subject matter under the two-step test of Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012). Sequenom's patent is premised on the breakthrough discovery that paternally inherited cell-free fetal DNA ("cffDNA") can be found in maternal plasma, material which prior to this discovery was discarded as waste. Although Sequenom's application of this discovery revolutionized prenatal diagnostics—making possible a noninvasive method for detecting prenatal defects without having to obtain fetal DNA directly from the fetus or placenta—the panel held that the claimed method was patent ineligible under Mayo. Applying Mayo's two-step test, the panel determined that 1) the claimed method "begins and ends with a natural phenomenon," and 2) the method steps are "well-understood, routine, and conventional." As a result, the panel concluded that the claimed method is not substantially more than a claim to the natural phenomenon itself. Judge Linn felt constrained by Mayo, stating that "[b]ut for the sweeping language in the Supreme Court's Mayo opinion, I see no reason, in policy or statute, why this breakthrough invention should be deemed patent ineligible."

Sequenom petitioned the court for rehearing en banc, arguing that the panel's failure to consider the claimed method as a whole was contrary to Diamond v. Diehr, 450 U.S. 175 (1981), Ass'n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013), and Mayo itself. The petition stated that "[i]t is inappropriate to dissect the claims into old and new elements and then to ignore the presence of the old elements," particularly because "a new combination of steps in a process may be patentable even though all the constituents of the combination were well known and in common use before the combination was made." Petition 8 (quoting Diehr). Sequenom's petition received strong support from amici from numerous organizations, companies and academic groups. There were 12 amicus briefs in total, raising a variety of additional arguments in support of en banc review.

A number of amici argued that preemption (of abstract ideas, laws of nature, and natural phenomena) had to be considered in assessing patent eligibility. The panel expressly recognized that "[t]he Supreme Court has made clear that the principle of preemption is the basis for the judicial exceptions to patentability." But despite undisputed evidence that Sequenom's claims do not preempt all uses of cffDNA, the panel held that "the absence of complete preemption does not demonstrate patent eligibility" and, where an invention is patent ineligible under the Mayo two-step test, "preemption concerns are fully addressed and made moot." In urging en banc review, the Intellectual Property Owners Association ("IPO") argued that "evidence of lack of preemption is never 'moot' under the Supreme Court's two-step test for patent eligibility." IPO Br. 10. The New York Intellectual Property Law Association ("NYIPLA") likened the panel's application of Mayo to the "rigid analysis of prior Supreme Court patent-eligibility frameworks [] rejected in Bilski v. Kappos, 561 U.S. 593 (2010)." NYIPLA Br. 6.1 The Wisconsin Alumni Research Foundation ("WARF"), along with the Marshfield Clinic and MCIS, Inc., also urged en banc review on preemption grounds. They distinguished between "a patent [that] impermissibly claims and prevents others from using a natural phenomenon, law of nature, or abstract idea itself" and a non-preemptive patent that "claims a practical application of one of those things." WARF Br. 5. They explained that "[b]ecause Sequenom's claims neither expressly nor practically monopolize the cffDNA that naturally appears in maternal fluids, they are patent-eligible under 35 U.S.C. § 101." Id. at 6.

Many of the amici discussed the consequences of the panel's decision to the biotech industry, particularly to diagnostics and personalized medicine. For example, Biotechnology Industry Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA") stated that the "dark cloud overshadowing thousands of issued and maintained biotechnology patents, many of which have been the basis for substantial investment, threatens investors' expectations that appeared reasonable prior to recent jurisprudential developments." BIO/PhRMA Br. 3. BIO and PhRMA noted that "the resulting uncertainty is affecting future investment decisions." Id. Indeed, as explained in the amicus brief of a group of twenty-three law professors, "[t]he economics of innovative diagnostic tests reflect exactly the economic justification for the patent system: the cost of applying a genetic diagnostic test is relatively low, but the ex ante R&D cost is enormous and is not reflected in the marginal cost of the medical test itself." Law Profs. Br. 3. In its amicus brief, Novartis stated that the "threat [the decision brings] begins with our own inventions related to personalized medicine, biomarkers and point-of-care testing, as well as the inventions of third parties upon which we now or may in the future depend to help meet our goal of providing the right medicine to the right patient at the right time." Novartis Br. 4.

The UK-based BioIndustry Association ("BIA") also urged en banc review. Its brief focused on the impact of the panel's decision on foreign companies and efforts to harmonize U.S. patent law with the rest of the world. The BIA noted that "approximately 50% of all U.S. patent applications are filed by foreign entities" and that "startups and fledgling businesses rely on the U.S. market projections for securing R&D funding, as the U.S. accounts for 47% of the global biotechnology market." BIA Br. 1-2. BIA expressed concern that the panel's decision "jeopardizes the future of much needed diagnostics" and may lead to an "exodus of investment and businesses from the US market or the life science industry in general." Id. at 2-3. BIA also described the panel's decision as a "setback in long-standing efforts to harmonize patent laws" and at odds with the patent eligibility standard of other nations. Id. at 2. BIA noted that the European counterpart of Sequenom's patent survived an opposition challenge and an appeal, with subject-matter eligibility never being an issue. Id. at 4-5. The European Patent Office's guidelines explain that the mere discovery of a "previously unrecognized substance occurring in nature" is unpatentable, but "if a substance found in nature can be shown to produce a technical effect, it may be patentable." Id. at 6. Due to the difference in patent eligibility for the same inventions in the U.S. and abroad, BIA fears that companies will "be forced to choose between patent protection in the rest of the world (except the U.S.) or trade secret protection everywhere." Id. at 2. It urged en banc review to avoid that outcome.

The depth and breadth of support for Sequenom's petition lends weight to Sequenom's request for en banc review. Indeed, last week the Federal Circuit invited appellees to respond to Sequenom's petition for rehearing en banc. The response is due on September 17, 2015.


1 Irena Royzman, Co-Chair of the NYIPLA Amicus Briefs Committee, was an author of NYIPLA's brief.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.